Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/55506
Título: Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients
Palavras-chave: Acute kidney injury
COVID-19
Kidney replacement therapy
Risk factors
Risk prediction
Score
Lesão renal aguda
Terapia renal substitutiva
Doença renal - Fatores de risco
Data do documento: Set-2022
Editor: Springer Nature
Citação: FIGUEIREDO, F. de A. et al. Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients. BMC Medicine, [S.I.], v. 20, 2022. DOI: https://doi.org/10.1186/s12916-022-02503-0.
Resumo: Background: Acute kidney injury (AKI) is frequently associated with COVID-19, and the need for kidney replacement therapy (KRT) is considered an indicator of disease severity. This study aimed to develop a prognostic score for pre‑ dicting the need for KRT in hospitalised COVID-19 patients, and to assess the incidence of AKI and KRT requirement. Methods: This study is part of a multicentre cohort, the Brazilian COVID-19 Registry. A total of 5212 adult COVID19 patients were included between March/2020 and September/2020. Variable selection was performed using generalised additive models (GAM), and least absolute shrinkage and selection operator (LASSO) regression was used for score derivation. Accuracy was assessed using the area under the receiver operating characteristic curve (AUC-ROC). Results: The median age of the model-derivation cohort was 59 (IQR 47–70) years, 54.5% were men, 34.3% required ICU admission, 20.9% evolved with AKI, 9.3% required KRT, and 15.1% died during hospitalisation. The temporal validation cohort had similar age, sex, ICU admission, AKI, required KRT distribution and in-hospital mortality. The geographic validation cohort had similar age and sex; however, this cohort had higher rates of ICU admission, AKI, need for KRT and in-hospital mortality. Four predictors of the need for KRT were identifed using GAM: need for mechanical ventilation, male sex, higher creatinine at hospital presentation and diabetes. The MMCD score had excellent discrimination in derivation (AUROC 0.929, 95% CI 0.918–0.939) and validation (tem‑ poral AUROC 0.927, 95% CI 0.911–0.941; geographic AUROC 0.819, 95% CI 0.792–0.845) cohorts and good overall performance (Brier score: 0.057, 0.056 and 0.122, respectively). The score is implemented in a freely available online risk calculator (https://www.mmcdscore.com/). Conclusions: The use of the MMCD score to predict the need for KRT may assist healthcare workers in identifying hospitalised COVID-19 patients who may require more intensive monitoring, and can be useful for resource allocation.
URI: http://repositorio.ufla.br/jspui/handle/1/55506
Aparece nas coleções:DME - Artigos publicados em periódicos

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
ARTIGO_Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients.pdf1,39 MBAdobe PDFVisualizar/Abrir


Este item está licenciada sob uma Licença Creative Commons Creative Commons